-

CCS Launches Scientific Advisory Council to Accelerate Advancements in Chronic Care Management

Four industry leaders announced as part of multi-stakeholder council that will advise on developing a more holistic approach to home-based care for patients living with chronic diseases like diabetes

DALLAS--(BUSINESS WIRE)--CCS — leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions — today announced the launch of its Scientific Advisory Council, which includes four industry leaders who will support CCS in its commitment to redefining patient care at home through a more holistic approach: Alexander Ding, MD, MBA; Karmeen Kulkarni, MS, RD, CD, CDCES, BC-ADM; Steven Wittlin, MD; and Francine Kaufman, MD. This news comes on the heels of the company’s recent announcement that Arti Masturzo, MD, joined CCS as its first-ever Chief Medical Officer.

“Dr. Masturzo has assembled a multi-stakeholder group of experts to comprise our newly formed Scientific Advisory Council,” said Tony Vahedian, Chief Executive Officer at CCS. “Dr. Ding, Ms. Kulkarni, Dr. Wittlin, and Dr. Kaufman each bring unique industry expertise to the council. Arti will lead the council in helping to inform new approaches to simplifying chronic care management for the patients we serve.”

Considering more than 11% of the U.S. population has already been diagnosed with diabetes and the projected rise in diabetes among American youth and young adults, the need for innovative partnerships, technologies, and services focused on fully supporting people in effectively managing their diabetes has never been greater. That’s why CCS chose to assemble its Scientific Advisory Council and take a leadership role in reimagining how providers, health plans, and employers support their patients and members living with costly, debilitating chronic diseases. The following provides more details on the inaugural members of the Council:

  • Alexander Ding, MD, MBA, is a practicing diagnostic and interventional radiologist, Associate Vice President of Physician Strategy and Medical Affairs at Humana, and a board member of the American Medical Association. He has deep expertise in nurturing physician-health plan relationships and in the advancement of digital health as a tool for patient engagement and empowerment.
  • Karmeen Kulkarni, MS, RD, CD, CDCES, BC-ADM, is a global clinical leader in diabetes management with more than 30 years of experience. Prior to spearheading her own consulting group, she spent 15 years with Abbott as the director of Global Scientific Affairs. Ms. Kulkarni brings a unique understanding of integrating devices, technology, coaching, and clinical services to drive measurable impact on outcomes for patients living with diabetes.
  • Steven Wittlin, MD, is an endocrinologist, frequently published author, and Director of Diabetes Services at the University of Rochester. His prior experience includes new modalities of therapy that integrate best practice approaches to medical devices, technology, and clinical services in the treatment of diabetes.
  • Francine Kaufman, MD is a practicing pediatric endocrinologist, Distinguished Professor Emerita of Pediatrics at the Keck School of Medicine of the University of Southern California and Children's Hospital Los Angeles, and the former president of the American Diabetes Association. She was the Chief Medical Officer at Medtronic Diabetes and currently holds that position at Senseonics, Inc. Dr. Kaufman has been serving as an integral member of the CCS Strategic Advisory Board and will now be included as part of this new Scientific Advisory Council.

“CCS is fundamentally redefining how care should be provided to people who are facing the fear and information overload associated with the diagnosis of a chronic disease,” said Dr. Masturzo. “I am energized to work hand-in-hand with these talented council members to fast-track the development of new clinical solutions that prioritize a simpler, more effective approach to home-based care for those living with diabetes and other chronic diseases.”

To learn more about CCS, please visit CCSMed.com.

About CCS

CCS is a leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions, particularly diabetes. CCS supports 150,000+ people living with chronic conditions in the United States and delivers more than 1.2 million shipments of medical supplies directly to their homes each year. The company works specifically with health plans, employers, and providers to offer both technology and hands-on educational services to holistically support members living with diabetes. After serving individuals for more than 25 years, CCS has the experience, data, and relationships in place to create a new era of home-based, proactive chronic care management. Entities managed by Riva Ridge Capital LP are the primary shareholder of CCS. To learn more about CCS, please visit CCSMed.com; LinkedIn; and Twitter.

Contacts

CCS


Release Versions

Contacts

More News From CCS

Pharmacists Strained as Diabetes Cases Rise, and Patients are Paying the Price

ST. PETERSBURG, Fla.--(BUSINESS WIRE)--To date, the availability of a pharmacist behind the counter of the local retail pharmacy has been an important resource for people living with chronic conditions like diabetes. However, as the number of diabetes patients continues to grow and pharmacy workloads increase, pharmacists are saying they lack the time and resources to provide the level of education and coaching patients need to stay healthy. According to a new report engaging more than 100 phar...

CCS Presents Four Peer-Reviewed Posters at American Diabetes Association’s 85th Scientific Sessions

CHICAGO--(BUSINESS WIRE)--CCS, a leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions, will present four peer-reviewed posters at the American Diabetes Association’s (ADA) 85th Scientific Sessions, which will take place June 20–23 in Chicago. These latest poster presentations illustrate CCS’s focus on delivering evidence-based approaches to diabetes care management that ensure patients have the education and coaching they need to th...

New Data Show CCS’s Predictive Analytics and Intervention Platform Is Highly Effective in Driving Continuous Glucose Monitoring Adherence in Medicare Population

ST. PETERSBURG, Fla.--(BUSINESS WIRE)--CCS, a leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions, announced new data-driven findings that show the company’s proprietary AI-enabled predictive analytics and intervention platform — PropheSee™ — effectively identified approximately 28 percent of 55,000 Medicare fee-for-service (FFS) patients at risk of lapsing on continuous glucose monitoring (CGM) therapy. As a result of applying CCS...
Back to Newsroom